ImmixBio TM  News

ImmixBio Announces Dr. Galit Lahav of Harvard Medical School Joins Scientific Advisory […]

ImmixBio In The News

Oncology biotech Immix Biopharma files for a $25 million IPO Renaissance Capital September 17, 2021 Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, filed on Friday with the SEC to raise up to $25 million in an initial public offering. Immix is […]
Newsletters – Term Sheet – IPOs Fortune September 17, 2021 “Immix Biopharma, a Los Angeles-based oncology drug company, filed for an initial public offering …” Original Article Link
BeiGene and Immix ink collaboration agreement for IMX-110/tislelizumab cancer study Seeking Alpha Aug. 27, 2021 8:47 AM ET By: Aakash Babu, SA News Editor     BeiGene (NASDAQ:BGNE) and Immix Biopharma announce a clinical trial and supply agreement to evaluate the safety, tolerability and efficacy of a […]
Immix Biopharma submits registration statement for IPO Seeking Alpha Jul. 23, 2021 11:11 AM ET By: Jonathan M Block, SA News Editor Immix Biopharma has confidentially submitted a draft registration statement (S-1 form) for an initial public offering. The number of shares to be offered and […]
West LA-Based Biotech ImmixBio – Maker of Cancer Treatments – Files for an IPO Keerthi Vedantam 03:52 PM | July 23, 2021 ImmixBio, a West L.A.-based startup developing cancer therapies, announced on Friday it submitted a confidential filing to go public. Ilya Rachman, chief executive […]
FierceBiotech FireceBiotech Chutes & Ladders Jul 9, 2021 9:30am “Immix Bio, focused on tissue-specific therapeutics for oncology and inflammation, chose Gabriel Morris as its chief financial officer and board member.” Original Article Link

About Us

Immix Biopharma, Inc. (ImmixBio TM) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific TM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. We use systems biology principles for rapid candidate selection and effective pre-clinical studies, leading to efficient manufacturing/scale up processes, toxicology and IP, followed by selection of appropriate contract research organizations and high-speed enrollment clinical trial sites.

ImmixBio was founded in 2012 by a visionary physician/entrepreneur, a world-renown pharmacology & drug delivery expert, a seasoned biotechnology patent attorney and an impact-driven founding family office.

Achieving impactful patient outcomes is what guides Immix. The team are not just experts in their fields – they have also been personally touched by cancer. With this deeply personal impetus, ImmixBio's objective is a qualitative response in each patient – nothing short.

In memory of Donald E. Senn, Ph.D. who tragically lost his life to cancer at the height of a vibrant career as a biomedical scientist, and to all of the cancer patients and their families around the world who continue their brave fight.